
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
by Barbara Tipton, Jeri Ann Boose, Joanne Beck, Thomas O'Brien, and William Larsen, CUNO Incorporated Two types of depth filters are studied for their ability to rid protein solutions of retroviruses and parvoviruses. Such filters are relatively economical and easy to use, so as secondary virus-removing devices, they are beneficial for downstream processing of mammalian cell cultures. Results indicate that depth filters are more effective on retroviruses than parvoviruses.
about 24 years ago
Reexamining the Set It and Forget It Approachabout 24 years ago
Security in the Corporate Homelandabout 24 years ago
Integrating New Technology into Blood Plasma Fractionationabout 24 years ago
Attack Mounts on Pharmaceutical Pricesabout 24 years ago
If a Tree Fell in the Forest





